AbCellera Biologics Inc. (ABCL) Stock Price & How to Invest

Last updated November 2026

Short answer

ABCL is AbCellera Biologics, a clinical-stage antibody company transitioning from a discovery-partner platform into a developer of its own drugs, so it trades more like a cash-rich, binary-catalyst biotech than a profitable operating business. After ABCL-635 met its primary efficacy endpoints in a Phase 2 menopause study, the shares roughly tripled in 2026 (up about 190% year to date as of November 20, 2026, to about $9.93, though down about 16% over the past month), and the company raised $200M in stock to fund late-stage development planned for 2027, so anyone considering it is underwriting ABCL-635's path to approval against a large cash cushion, not near-term earnings.

ABCL stock price

As of 2026-11-20, AbCellera Biologics Inc. (ABCL) last closed at $9.69, up 176.1% over the past year. Over the past 52 weeks it has traded between $2.78 and $14.82.

ABCL last close
$9.69
1 day
-7.45%
1 month
-20.83%
1 year
+176.07%
52-week range
$2.78 to $14.82
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or AbCellera Biologics Inc.'s investor relations page. Walnut is informational, not investment advice.

ABCL key stats

At $9.69 on November 20, 2026, AbCellera Biologics Inc. (ABCL) has a market cap of $3.2B.

Market cap
$3.2B
Price to book
3.0
Beta
1.59

Market cap, P/E and yield are measured at the $9.69 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with AbCellera Biologics Inc. (ABCL)?

The last two weeks for AbCellera Biologics Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • ABCL closed at $9.69 on November 20, 2026, down 15.7% over the past five trading days (from $11.49).
  • On November 9, 2026, AbCellera Biologics Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 9, 2026, AbCellera Biologics Inc. filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
  • On November 16, 2026, Piper Sandler raised its target to $20.00 from $12.00 (Overweight).
  • On November 11, 2026, StoneX raised its target to $15.00 from $11.00 (Buy).
  • On November 10, 2026, Stifel raised its target to $14.00 from $9.00 (Buy).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

AbCellera Biologics Inc. (ABCL) latest quarter

AbCellera reported revenue of $10.6 million for Q3 2026, up 19% from a year earlier (AbCellera, Nov 9, 2026).

Revenue
$10.6 million
up 19% from a year earlier
Diluted EPS
-$0.13
n/a
Research fees
$10.5 million
up 20% from a year earlier

Source: AbCellera Q3 2026 results, Nov 9, 2026. Full earnings breakdown

What does AbCellera Biologics Inc. (ABCL) do?

AbCellera Biologics (Nasdaq: ABCL) built an AI-assisted, single-cell antibody-discovery platform (spun out of the University of British Columbia) that it originally rented to pharma partners such as Eli Lilly, Regeneron, AbbVie and Biogen in exchange for research fees, milestones and downstream royalties. Since 2023 it has deliberately scaled back partnership volume to redirect resources into its own internal pipeline, moving from a services-and-royalties model toward being a clinical-stage drug developer that captures more of the upside if its molecules succeed.

The investment picture is a classic pre-profit biotech setup: modest and lumpy platform revenue (about $68M over the trailing twelve months, with about $10.6M in Q3 2026), sizeable R&D-driven net losses (about $148M trailing), and a large balance sheet (about $764M in cash, equivalents and marketable securities at September 30, 2026, after a $200M share and pre-funded warrant offering that brought net proceeds of about $189M, plus more than $100M of non-dilutive government funding) meant to fund the pipeline for years. The story now rides mainly on one lead asset. ABCL-635, a non-hormonal NK3R antibody for menopausal hot flashes, met its primary efficacy endpoints in Phase 2 with improvements in sleep and patient-reported outcomes, and AbCellera expects to start late-stage development in 2027, plus trials in hot flashes caused by breast and prostate cancer hormone therapy. ABCL-575 for atopic dermatitis met all its Phase 1 endpoints, but the company does not plan to develop it further. The stock is up about 190% year to date as of November 20, 2026, with a market cap near $3.2B, but it has fallen about 21% over three months from a 52-week high near $15, so some of the ABCL-635 optimism has already come back out of the price.

What's driving AbCellera Biologics Inc. (ABCL)?

1. ABCL-635 heads toward late-stage trials

AbCellera has one internal candidate now driving the story. ABCL-635 (a potential first-in-class NK3R antibody for menopausal hot flashes) met its primary efficacy endpoints in a randomized, placebo-controlled Phase 2 study, with significant reductions in the frequency and severity of moderate-to-severe hot flashes, favorable tolerability and improvements in sleep, after interim Phase 1 data showed a clean safety profile and an ~24-day half-life supporting once-monthly dosing. The company plans to start late-stage development in 2027 and to open trials in hot flashes caused by hormone suppression from breast and prostate cancer treatment the same year, and ABCL-992, a half-life extended version of ABCL-635, has entered IND-enabling work. ABCL-575 for atopic dermatitis met all Phase 1 endpoints, but AbCellera does not plan to develop it beyond Phase 1.

2. Deep cash runway

AbCellera held about $764M in cash, equivalents and marketable securities at September 30, 2026 against roughly $134M of debt, and it cites more than $890M of total available liquidity including over $100M of non-dilutive government funding. The jump came from a $200M offering of common shares and pre-funded warrants after the ABCL-635 data (net proceeds about $189M), which raised shares outstanding from about 300.6M to 326.3M. Operating cash flow was positive year to date (about $19M) thanks to partner payments. That balance sheet lets it push late-stage trials without immediate reliance on further dilutive raises, a meaningful advantage for a pre-revenue-scale biotech.

3. Platform and royalty optionality

AbCellera has completed over 100 antibody-discovery programs and retains downstream milestone and royalty rights across many partner programs, plus blue-chip relationships (Eli Lilly, Regeneron, AbbVie, Biogen). Any partner-program approvals could add royalty streams on top of the internal pipeline, giving a second, lower-cost source of potential upside. Partner revenue stays lumpy: Q4 2025 brought about $45M, Q2 2026 about $4M and Q3 2026 about $10.6M. Partners were leading 34 programs in which AbCellera holds a downstream stake at September 30, 2026, down from 44 at the end of 2025, with 12 of those molecules in the clinic.

4. Expanding earlier-stage pipeline

Beyond ABCL-635, AbCellera is advancing ABCL-688 and ABCL-386 through IND-enabling work with a target of entering clinical trials by 2027, and three new programs entered IND-enabling work in 2026: ABCL-992, ABCL-385 (oncology) and ABCL-646 (an ion channel antagonist). ABCL-635 is also the first program from its GPCR and ion-channel platform to reach the clinic, so its progress tests that platform as a source of further drugs. This widening internal pipeline is how management intends to build a durable, multi-shot-on-goal drug portfolio rather than a single-asset bet.

What are the risks to AbCellera Biologics Inc. (ABCL)?

AbCellera is unprofitable and burning cash at the operating level, posting a net loss of about $41M in Q3 2026 on about $10.6M of quarterly revenue, so the market value rests on future clinical success, not current earnings. After a roughly 190% gain in 2026 the stock carries high expectations for ABCL-635, and with ABCL-575 shelved after Phase 1 the company is closer to a single-asset story: weaker late-stage data, safety findings (liver monitoring is a known issue in the NK3R class), or competition from approved non-hormonal therapies could sharply reset the valuation. The 2026 offering already diluted holders by about 8% in share count, and late-stage trials are expensive. Platform revenue has fallen far from its pandemic-era peak (when Lilly antibody royalties were large), is lumpy and partner-dependent, and the number of partner-led programs fell to 34 from 44 this year. Drug development carries the usual risks of trial failure, regulatory delay and competition in crowded indications, and while the cash runway is long, sustained losses (analysts expect about -$0.61 EPS for 2026 and -$0.70 for 2027) could eventually require more financing.

What is the AbCellera Biologics Inc. (ABCL) forecast?

13 analysts publish price targets on ABCL, averaging $18.69 as of November 2026, or +92.9% against the $9.69 share price on November 20, 2026. The published targets run from $14.00 to $30.00, a wide spread, and the ratings split 13 buy, 1 hold, 0 sell. Over the last six months there have been 6 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ABCL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is ABCL a buy or a sell?

We give no verdict on AbCellera Biologics Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. ABCL-635 heads toward late-stage trials. AbCellera has one internal candidate now driving the story. The most optimistic published target, $30.00, assumes this works close to its best case.

The case against. AbCellera is unprofitable and burning cash at the operating level, posting a net loss of about $41M in Q3 2026 on about $10.6M of quarterly revenue, so the market value rests on future clinical success, not current earnings. The most pessimistic target, $14.00, is roughly what ABCL is worth if this bites instead.

Read the full bull and bear case on ABCL, including what would have to change to break either one. Walnut is not an investment adviser.

Has AbCellera Biologics Inc. (ABCL) split its stock?

No. AbCellera Biologics Inc. (ABCL) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is AbCellera Biologics Inc. (ABCL) valued?

Market cap, P/E and dividend yield at today's price are in the ABCL key stats above. The business figures below come from AbCellera Biologics Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$68M
  • Revenue (Q3 2026): ~$10.6M (up ~19% yr-ago)
  • Net loss (TTM): ~$148M (Q3 2026 ~$41M)
  • Cash / debt: ~$764M / ~$134M

As of November 2026: AbCellera has no P/E because it is unprofitable, so investors typically frame it on cash-versus-market-cap and pipeline optionality. After the offering, cash covers about a quarter of the roughly $3.2B market value, up from about a seventh in October, as the share price fell and the cash pile grew, so most of the price still reflects expectations for ABCL-635. Analysts remain upbeat, with an average target near $18.69 across 13 analysts and a strong buy consensus.

Who competes with AbCellera Biologics Inc. (ABCL)?

Antibody-platform and discovery specialists

Adimab, Genmab and Crescendo Biologics compete on antibody-discovery technology and pipelines. These firms vie for the same partner relationships and target space where AbCellera historically earned research fees and royalties.

Research tools and CRO providers

Charles River Laboratories, 10x Genomics and Bruker Cellular Analysis supply discovery services and single-cell tools that overlap with parts of AbCellera's platform, giving pharma buyers alternatives to outsourcing antibody discovery to AbCellera.

Clinical-stage biotech peers in its indications

As AbCellera develops its own drugs it now competes with companies pursuing menopausal vasomotor symptoms (for example non-hormonal NK-receptor approaches, a class where approved oral drugs already exist) and atopic dermatitis, where established antibody therapies and other developers already target the same patient populations.

What stocks are similar to AbCellera Biologics Inc. (ABCL)?

Other names that sit close to ABCL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in AbCellera Biologics Inc. (ABCL)

There are three common ways to get ABCL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ABCL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ABCL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on AbCellera Biologics Inc. (ABCL)

AbCellera is a well-funded, pre-profit antibody developer whose value now leans heavily on ABCL-635 after a positive Phase 2 and a decision not to take ABCL-575 past Phase 1, so it fits an investor comfortable with high-variance, catalyst-driven biotech risk and a share price that has already re-rated sharply.

More on AbCellera Biologics Inc. (ABCL)

Whether ABCL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ABCL a buy or a sell?, and where the stock could go from here in the ABCL stock forecast.

For income investors, whether ABCL pays a dividend and how the payout looks is covered in does ABCL pay a dividend? And to weigh ABCL against a peer, read the full side-by-side comparisons: ABCL vs GMAB and ABCL vs CRL.

Wondering how ABCL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about AbCellera Biologics Inc.

Ask Walnut's AI anything about ABCL and see how it fits what you own.

FAQ

What does AbCellera Biologics do?

+

AbCellera uses an AI-assisted, single-cell antibody-discovery platform to find therapeutic antibodies. It historically partnered with drugmakers for fees and royalties and is now developing its own antibody drugs in-house, shifting from a services model toward being a clinical-stage developer.

Is AbCellera profitable?

+

No. AbCellera is a pre-profit biotech that posted a net loss of about $41M in Q3 2026 on roughly $10.6M of revenue, and about $148M over the trailing twelve months. Like most clinical-stage companies, it spends heavily on R&D and funds itself from a large cash balance, not operating profit.

How much cash does AbCellera have?

+

AbCellera reported about $764M in cash, equivalents and marketable securities at September 30, 2026 against roughly $134M of debt, boosted by a $200M stock and pre-funded warrant offering after the ABCL-635 data. Including more than $100M of non-dilutive government funding, it cites over $890M of total available liquidity, a multi-year runway to advance its pipeline.

What are AbCellera's lead drug candidates?

+

Its lead asset is ABCL-635, an antibody for menopausal vasomotor symptoms (hot flashes) that met its primary efficacy endpoints in Phase 2; late-stage development is expected to start in 2027. ABCL-575 for atopic dermatitis met all Phase 1 endpoints but will not be developed further. ABCL-688, ABCL-386, ABCL-992, ABCL-385 and ABCL-646 are in IND-enabling work.

Why is ABCL stock so volatile?

+

Because most of its value depends on future clinical outcomes rather than current earnings. In 2026 the shares ranged from about $2.74 to $15.02 as ABCL-635 data arrived. Binary trial readouts, small and lumpy revenue, and shifting analyst expectations can move the shares sharply in either direction, which is typical for catalyst-driven biotech names.

Who are AbCellera's partners and competitors?

+

It has worked with large drugmakers including Eli Lilly, Regeneron, AbbVie and Biogen. Competitors include antibody specialists like Adimab and Genmab, research-tool and CRO providers like Charles River and 10x Genomics, and clinical-stage peers in its target indications.

How does AbCellera make money?

+

Today its revenue comes mainly from partner research fees, milestone payments and downstream royalties from its discovery platform. Over time management is betting on capturing more value by developing and potentially commercializing its own antibody drugs.

How can I invest in ABCL?

+

ABCL trades on the Nasdaq and can be bought through any standard brokerage that offers US equities. With Walnut you can add it to a thematic basket and track it alongside related biotech holdings. Walnut is not an investment adviser, so any decision is your own.

How has ABCL stock performed in 2026?

+

As of November 20, 2026, ABCL closed near $9.93, up about 190% year to date and 191% over one year, but down about 21% over three months and 16% over the past month from a 52-week high near $15 set around the ABCL-635 Phase 2 news. Past moves are not a guide to future returns.

How did AbCellera do in its latest quarter?

+

In Q3 2026, reported November 9, AbCellera posted revenue of about $10.6M, up from $9.0M a year earlier, and a net loss of about $40.8M, or -$0.13 per share versus a -$0.18 consensus. It ended the quarter with about $764M in cash and marketable securities after its $200M offering, and said it delivered on all its 2026 corporate priorities.

Why did AbCellera stop developing ABCL-575?

+

ABCL-575, an OX40 ligand antibody for atopic dermatitis, met all its Phase 1 endpoints with favorable tolerability and a pharmacokinetic profile supporting extended dosing. In its Q3 2026 report AbCellera said it does not currently plan to develop it beyond Phase 1, concentrating spending on ABCL-635 and earlier programs. That leaves ABCL-635 as the only internal asset headed for late-stage trials.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with AbCellera Biologics Inc.'s investor relations page or your broker before making investment decisions.